<DOC>
	<DOCNO>NCT02559037</DOCNO>
	<brief_summary>The purpose study observe efficacy safety acupuncture moxibustion Crohn 's disease regulation mechanism intestinal microbiota mucosal immunity .</brief_summary>
	<brief_title>Acupuncture Moxibustion Treatment Crohn 's Disease</brief_title>
	<detailed_description>1 . A randomized controlled trial . 2 . Acupuncture moxibustion treatment , placebo control . 3 . To observe efficacy safety acupuncture moxibustion treatment versus placebo control Crohn 's disease . 4 . To observe effect regulation intestinal microbiota Crohn 's disease . 5 . To observe effect regulation mucosal immunity Crohn 's disease .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1. meet diagnostic criterion Crohn 's disease ; 2. age 1670 3. patient mild moderate CD ( CDAI 151 360 ) ; 4. take medication take mesalazine , prednisone ( dose â‰¤15mg take least one month ) , patient enter study maintain dose unchanged ; 5. take immunosuppressive drug biological agent infliximab within 3 month enter study ; 6. agree sign informed consent . 1. pregnant lactating patient ; 2. associated heart , brain , liver , kidney hematopoietic system serious disease ; 3. mental illness ; 4. serious disease ; 5. presence skin disease , fistula , sinus , mutilation condition acupoints select study implement moxibustion treatment .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acupuncture</keyword>
	<keyword>moxibustion</keyword>
	<keyword>intestinal microbiota</keyword>
	<keyword>Mucosal immunity</keyword>
</DOC>